CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 125 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $16,639,000 | -8.4% | 3,269,112 | +13.9% | 0.02% | -5.9% |
| Q2 2021 | $18,160,000 | -15.2% | 2,868,986 | +3.6% | 0.02% | -22.7% |
| Q1 2021 | $21,403,000 | +41.0% | 2,768,882 | +19.5% | 0.02% | +29.4% |
| Q4 2020 | $15,179,000 | -6.0% | 2,317,397 | -4.5% | 0.02% | -19.0% |
| Q3 2020 | $16,145,000 | -14.9% | 2,427,806 | +6.6% | 0.02% | -19.2% |
| Q2 2020 | $18,967,000 | -55.4% | 2,276,960 | -58.9% | 0.03% | -27.8% |
| Q1 2020 | $42,530,000 | +81.9% | 5,544,852 | +97.1% | 0.04% | +28.6% |
| Q4 2019 | $23,380,000 | +20.8% | 2,813,451 | +7.3% | 0.03% | +12.0% |
| Q3 2019 | $19,351,000 | -13.2% | 2,622,122 | +32.0% | 0.02% | -44.4% |
| Q2 2019 | $22,283,000 | +25.2% | 1,985,990 | +20.0% | 0.04% | +12.5% |
| Q1 2019 | $17,797,000 | +28.1% | 1,655,530 | +79.9% | 0.04% | +14.3% |
| Q4 2018 | $13,895,000 | -15.6% | 920,210 | +3.3% | 0.04% | +2.9% |
| Q3 2018 | $16,472,000 | +514.2% | 890,400 | +658.9% | 0.03% | +466.7% |
| Q2 2018 | $2,682,000 | -24.0% | 117,320 | -5.4% | 0.01% | -25.0% |
| Q1 2018 | $3,529,000 | – | 124,030 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
| MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
| Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
| Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
| Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
| BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
| RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
| EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
| DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
| HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |